Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 15/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPRS1 | P07814 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716685 | 0.84 | L3MBTL1 (0.34) | PDE2ASMN1; SMN2EPRS1HRH4 | |
| SCHEMBL2115559 | 0.81 | MAPT (0.43) | SMN1; SMN2 | |
| SCHEMBL616122 | 0.72 | LMNA (0.33) | PDE2ASMN1; SMN2 | |
| SCHEMBL715781 | 0.71 | — | — | |
| SCHEMBL715780 | 0.71 | — | — | |
| SCHEMBL14482160 | 0.69 | MEN1 (0.35) | PDE2AEPRS1 | |
| SCHEMBL2117089 | 0.68 | ALDH1A1 (0.42) | SMN1; SMN2EPRS1 | |
| SCHEMBL17530830 | 0.67 | — | — | |
| SCHEMBL17530832 | 0.67 | — | — | |
| SCHEMBL863617 | 0.67 | ALDH1A1 (0.35) | SMN1; SMN2EPRS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | PDE2A 1300/4885EGLN1 3864/4885SMN1; SMN2 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.